1) Variations in NT-proBNP levels between week 6 and randomization. 2) Variations in body weight, ketone body, and HbA1c, and echocardiographic parameters for diastolic dysfunction, left ventricular end-systolic volume (LVESV), and end-diastolic volume (LVEDV) from randomization to weeks 6 and 26. 3) Hospitalizations for heart failure or other reasons, length of hospital stay, and overall mortality were additional exploratory goals. Here, NPPB is linked to heart failure.